ライフサイエンスコーパス: nitroimidazole

1 sequential four-drug regimens that include a nitroimidazole.

2 belonging to both assemblages A and B, after nitroimidazole.

3 ory proteins that directly interact with the nitroimidazole.

4 f the hypoxic cell marker pentafluorinated 2-nitroimidazole.

5 ted in patients with giardiasis treated with nitroimidazoles.

6 n be monitored by measuring the binding of 2-nitroimidazoles.

7 aching over 70% for most of the considered 5-nitroimidazoles.

8 wide range of substituted aryl halides and 4-nitroimidazoles.

9 f refractory giardiasis after treatment with nitroimidazoles.

10 of structure-based optimization of improved nitroimidazoles.

11 alize MIC results in this series of bicyclic nitroimidazoles.

12 btle structural variations in these bicyclic nitroimidazoles.

13 is hypothesis, we synthesized a 10B-enriched nitroimidazole, 1-2[(undecahydro-closo-dodecaborato)thio

14 By using the hypoxic marker 2-(2-nitroimidazole-1[H]-y1)-N-(2,2,3,3,3-pentafluoropropyl)-

15 le (10), 1-(2'-deoxy-beta-D-ribofuranosyl)-4-nitroimidazole (11) and 1-(2'-deoxy-beta-D-ribofuranosyl

16 alpha-D-[5-fluoro-5-deoxyarabinofuranosyl]-2-nitroimidazole [(18)F-FAZA]).

17 g(-1)) and the recommended concentration for nitroimidazole (3.00 mug kg(-1)), respectively.

18 ric Ru(II)(kappa(4)-bda)L(2) complexes L = 5-nitroimidazole (5) and 5-bromo-N-methylimidazole (6), th

19 t has been developed for the extraction of 5-nitroimidazole (5-NDZ) drugs in milk samples previous to

20 dia lamblia, are commonly treated with the 5-nitroimidazole (5-NI) metronidazole (Mz), and yet treatm

21 Metronidazole and other 5-nitroimidazoles (5-NI) are among the most effective anti

22 beta-D-erythro-pentofuranosyl)-5-guanidino-4-nitroimidazole (6a) was synthesized by an independent ro

23 In the first step, 2-nitroimidazole (8) is coupled with 10 to yield intermedi

24 , fluoroquinolones (11), sulphonamides (17), nitroimidazoles (9), amphenicols (2), cephalosporins (7)

25 In contrast, 5-guanidino-4-nitroimidazole, a product of the oxidation of guanine in

26 be used as potential biomarkers of illicit 5-nitroimidazole abuse.

27 The fluorinated nitroimidazoles all showed radiotracer uptake increasing

28 rmation of the nitro products, 5-guanidino-4-nitroimidazole and 8-nitroguanine adducts.

29 ared from zinc(II) nitrate and mixtures of 2-nitroimidazole and five different functionalized imidazo

30 In particular, hyperpolarized nitroimidazole and its derivatives have powerful potenti

31 have synthesized analogues of both 4- and 5-nitroimidazoles and explored their antitubercular activi

32 ven patients were recruited and treated with nitroimidazoles, and in 14 of 71 (20%) of patients follo

33 d with single-dose therapy of an appropriate nitroimidazole antibiotic, but women who are also infect

34 nt studies of azathioprine/6-mercaptopurine, nitroimidazole antibiotics, and infliximab have broadene

35 The CYP3A inhibitors used in the study were nitroimidazole antifungal agents, diltiazem, verapamil,

36 previously shown to mediate resistance to 5-nitroimidazole antimicrobial agents in B. fragilis strai

37 te that 2-aminoimidazolone and 5-guanidino-4-nitroimidazole are potent sources of mutations in vivo.

38 Nitroimidazoles are a class of antimicrobial drugs that

39 g either 2-aminoimidazolone or 5-guanidino-4-nitroimidazole at a specific site, were ligated into sin

40 Several 2-nitroimidazole-based molecules (NIs) are used as clinica

41 Some of the best nitroimidazole CA IX inhibitors showed significant activ

42 le and CGI-17341, PA-824 is a prodrug of the nitroimidazole class, requiring bioreductive activation

43 ,3,3,3-pentafluoropropyl)acetam ide (EF5), a nitroimidazole compound that binds selectively to hypoxi

44 vestigated the mechanism by which fungicidal nitroimidazole compounds modulate AC activity.

45 The 2-nitroimidazole containing lead compound 3b (TH-302) was

46 f association under hypoxic conditions for 2-nitroimidazole-containing BB2r-targeted radioconjugates

47 ecific 2-aminoimidazolone- and 5-guanidino-4-nitroimidazole-containing genomes, and analysis of the r

48 Pd- or Ni-catalyzed C-H arylation of 4-nitroimidazole derivatives directed by a manipulable nit

49 ites; the major one is the corresponding des-nitroimidazole (des-nitro).

50 that this nitration product is 5-guanidino-4-nitroimidazole diphosphate (NIm-DP), a degradation produ

51 Localization and quantitation of 2-nitroimidazole drug binding in low pO2 tumors is a techn

52 d, and contemporary strategies to facilitate nitroimidazole drug development are highlighted.

53 urther evidence of the toxic mechanisms of 5-nitroimidazole drugs has been revealed, which may be of

54 However, it can be further sensitized with nitroimidazole drugs, implying that it is partially hypo

55 increased degree of hypoxia (measured by the nitroimidazole EF5).

56 We used immunohistochemical detection of the nitroimidazole EF5, administered by intravascular infusi

57 method measures intracellular binding of the nitroimidazole EF5, which covalently binds to cellular m

58 ohistochemical detection of binding of the 2-nitroimidazole EF5.

59 ng of EF5, a fluorinated derivative of the 2-nitroimidazole, Etanidazole, can predict radioresistance

60 10B12H11SH) with 1-(2-bromoethyl)-2-methyl-5-nitroimidazole followed by purification of the adduct.

61 5-Guanidino-4-nitroimidazole formation in peroxynitrite-treated DNA wa

62 The yield of 5-guanidino-4-nitroimidazole formed in single-stranded DNA was approxi

63 hypoxia was investigated in vivo using the 2-nitroimidazole hypoxia marker, pimonidazole.

64 vation in hypoxic cells similar to that of 2-nitroimidazole hypoxia PET tracers.

65 o-closo-dodecaborato)thio]ethyl]-2- methyl-5-nitroimidazole (imidocaptate), by coupling the Cs salt o

66 he G to A mutation elicited by 5-guanidino-4-nitroimidazole implicates this lesion as a novel source

67 st that 2-aminoimidazolone and 5-guanidino-4-nitroimidazole in DNA are substrates for one or more of

68 The retention of nitroimidazole in Group 1 rabbits (brief occlusion) was

69 f the guanine-derived product, 5-guanidino-4-nitroimidazole, in synthetic oligonucleotides and DNA tr

70 ey determinants of aerobic activity in the 4-nitroimidazoles include the bicyclic oxazine, the lipoph

71 Bicyclic nitroimidazoles, including PA-824, are exciting candidat

72 A series of nitroimidazoles incorporating sulfonamide/sulfamide/sulf

73 midazolone; however, bypass of 5-guanidino-4-nitroimidazole increased nearly 10-fold.

74 was determined using the nucleoside analogs nitroimidazole, inosine, 7-deazaguanosine and 2-pyrimidi

75 rporation of the hypoxia-selective prodrug 2-nitroimidazole into receptor-targeted peptides.

76 nstrated that incorporation of one or more 2-nitroimidazoles into the BB2r-targeted peptide significa

77 ake of [18F]FETA in liver suggests that this nitroimidazole is metabolized less than [18F]FMISO.

78 he Suzuki-Miyaura cross-coupling reaction of nitroimidazoles is slightly lower in comparison to the d

79 re, we report that one lesion, 5-guanidino-4-nitroimidazole, is a substrate for multiple SOS polymera

80 Metronidazole, a 5-nitroimidazole, is often used as empirical therapy for a

81 Nitroimidazoles labeled with positron-emitting radionucl

82 bic Mycobacterium tuberculosis (Mtb) while 5-nitroimidazoles like metronidazole are active against on

83 xperiments further showed that 5-guanidino-4-nitroimidazole may cause G-->T and G-->C transversions i

84 st that nuclear DNA containing 5-guanidino-4-nitroimidazole may not be quickly repaired by DNA repair

85 tramethylpiperidin-N-oxyl (4, TEMPO) and the nitroimidazole misonidazole (5).

86 oligonucleotide containing the 5-guanidino-4-nitroimidazole modification was only partially cleaved b

87 ligonucleotides containing the 5-guanidino-4-nitroimidazole modification were purified by reverse-pha

88 the BB2r-targeted agents that incorporated 2-nitroimidazole moieties demonstrated improved retention.

89 2, (111) IN-3, and (111) IN-4, composed of 2-nitroimidazole moieties of 0, 1, 2, and 3, respectively-

90 st other HAP, including the clinical stage 2-nitroimidazole mustard TH-302, dinitrobenzamide mustard

91 For the 5-nitroimidazoles, neither the corresponding bicyclic anal

92 ve hyaluronic acid (HS-HA) conjugated with 2-nitroimidazole (NI), a hydrophobic component that can be

93 5-Guanidino-4-nitroimidazole (NI), derived from guanine oxidation by r

94 ard dinucleotide template indicated that the nitroimidazole nucleoside analogs could be used to incre

95 This study evaluates a new 99mTc-labeled nitroimidazole of potential benefit in standard myocardi

96 re synthesized in five steps starting from 4-nitroimidazole, others were derived from 1a through simp

97 The 4-nitroimidazole PA-824 is active against aerobic and anae

98 a in pancreatic cancer patients, using the 2-nitroimidazole PET tracer (18)F-fluoroazomycin arabinosi

99 While the 4-nitroimidazole portion was specifically required, severa

100 We postulated that nitroimidazoles, previously used for radiosensitizing so

101 The hetero-bifunctional nitroimidazole radiosensitizer CI-1010, R-alpha-[[(2-bro

102 Prodrugs activated by 2-nitroimidazole reduction demonstrated up to 400-fold enh

103 determination of nitrofuran metabolites and nitroimidazole residues in honey.

104 s AHD, AOZ, AMOZ and SEM, respectively while nitroimidazole residues; ronidazole (RNZ) and dimetridaz

105 RNA gene for identification purposes and the nitroimidazole resistance (nim) gene for detection of re

106 nization as the mobilization region of the 5-nitroimidazole resistance plasmid pIP417 and the clindam

107 In contrast, nitroimidazole retention in Groups 2 and 3 increased wit

108 The pattern of nitroimidazole retention on autoradiographs was then com

109 inhibitors, the most potent being 5-amino-4-nitroimidazole ribonucleotide with a K(i) of 0.7 +/- 0.5

110 The fluorinated nitroimidazoles showed similar tumor distributions when

111 in the presence and absence of 2-methyl-4(5)-nitroimidazole, showing impressive rate enhancements of

112 2-Nitroimidazoles, such as pimonidazole, are reduced in ce

113 is review, we summarize different classes of nitroimidazoles that have been described in the literatu

114 tumor and skin from patients given EF5, a 2-nitroimidazole tissue hypoxia monitor.

115 to use the hypoxia-trapping capability of 2-nitroimidazoles to increase the retention of the agent i

116 ties of 2-aminoimidazolone and 5-guanidino-4-nitroimidazole, two products of peroxynitrite oxidation

117 In contrast, 5-guanidino-4-nitroimidazole was a strong block to replication and 50%

118 Technetium-99m-labeled nitroimidazole was administered to rabbits during the ea

119 With calf thymus DNA, 5-guanidino-4-nitroimidazole was dose-dependently formed at low peroxy

120 temperature, the modified base 5-guanidino-4-nitroimidazole was generated along with several other pr

121 were characterized, and their modulation by nitroimidazoles was investigated.

122 or 14 days; 500 mg clarithromycin and 500 mg nitroimidazole were added, twice daily for the final 7 d

123 While nitroimidazoles were discovered in the 1950s, there has

124 d 5-nitroimidazooxazine provided the first 5-nitroimidazole with aerobic activity.